Grace Therapeutics, Inc. (GRCE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

Revenue Annual

0 35M 70M 105M FY21: 196K FY22: 100M FY21 FY22

Gross Profit Annual

0 35M 70M 105M FY21: 120K FY22: 100M FY21 FY22

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-60M -40M -20M 0 20M 40M 60M FY19: -34.4M FY20: -24.4M FY21: -16.4M FY22: -15.6M FY23: -52.2M FY24: -12.9M FY25: -16.7M FY26: -11.1M FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Net Income Annual

-45M -30M -15M 0 15M 30M 45M FY19: -39.4M FY20: -25.5M FY21: -19.7M FY22: -9.8M FY23: -42.4M FY24: -12.9M FY25: -9.6M FY26: -7.8M FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Cost of Revenue Annual

0 30K 60K 90K FY21: 76K FY22: 0 FY21 FY22

Operating Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY20: -23M FY21: -14.3M FY22: -17.2M FY23: -15.9M FY24: -12.3M FY25: -14.9M FY26: -8.9M FY20 FY21 FY22 FY23 FY24 FY25 FY26

Free Cash Flow Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Annual

0 20M 40M 60M FY18: 17.5M FY19: 54.3M FY22: 36.8M FY23: 7.4M FY24: 9.5M FY25: 12.1M FY26: 16.5M FY18 FY19 FY22 FY23 FY24 FY25 FY26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q4 '20: -0.30 Q1 '21: -0.24 Q2 '21: -0.51 Q3 '21: -0.63 Q4 '21: -0.98 Q1 '22: -1.05 Q2 '22: -0.56 Q3 '22: -0.39 Q4 '22: -0.28 Q1 '23: -0.77 Q2 '23: -1.40 Q3 '23: -1.83 Q4 '23: -5.70 Q1 '24: -5.63 Q2 '24: -5.40 Q3 '24: -5.09 Q4 '24: -1.44 Q1 '25: -1.14 Q2 '25: -1.01 Q3 '25: -1.16 Q4 '25: -0.79 Q1 '26: -0.76 Q2 '26: -0.52 Q3 '26: -0.30 Q4 '26: -0.47 Q1 '27: -1.17 Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q1 '26 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.